Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
25.81
-0.03 (-0.12%)
At close: Jul 2, 2026, 4:00 PM EDT
25.50
-0.31 (-1.20%)
After-hours: Jul 2, 2026, 5:39 PM EDT
Arcutis Biotherapeutics Employees
Arcutis Biotherapeutics had 354 employees as of December 31, 2025. The number of employees increased by 12 or 3.51% compared to the previous year.
Employees
354
Change (1Y)
12
Growth (1Y)
3.51%
Revenue / Employee
$1,174,079
Profits / Employee
-$6,712
Market Cap
3.23B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 354 | 12 | 3.51% |
| Dec 31, 2024 | 342 | 46 | 15.54% |
| Dec 31, 2023 | 296 | 28 | 10.45% |
| Dec 31, 2022 | 268 | 121 | 82.31% |
| Dec 31, 2021 | 147 | 93 | 172.22% |
| Sep 30, 2021 | 143 | 90 | 169.81% |
| Jun 30, 2021 | 108 | 59 | 120.41% |
| Mar 31, 2021 | 75 | 32 | 74.42% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ultragenyx Pharmaceutical | 1,371 |
| Beam Therapeutics | 522 |
| Tarsus Pharmaceuticals | 370 |
| Vera Therapeutics | 339 |
| Alumis | 227 |
| uniQure | 221 |
| Celldex Therapeutics | 198 |
| Disc Medicine | 154 |
ARQT News
- 2 days ago - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 days ago - Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications - GlobeNewsWire
- 5 days ago - FDA approves supplemental NDA to expand indication of Arcutis’ Zoryve cream - TheFly
- 5 days ago - FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2 - GlobeNewsWire
- 25 days ago - Arcutis Biotherapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - Arcutis Biotherapeutics Transcript: AGM 2026 - Transcripts
- 4 weeks ago - New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology - GlobeNewsWire
- 5 weeks ago - Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference - GlobeNewsWire